drugset / Trial / NCT03217422

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

NCT03217422

Phase 2/3 Completed 68 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

VAY736 dose testing; VAY736 efficacy and safety testing.

Timeline

Start
2018-02-15
Primary completion
2023-12-28
Completion
2025-12-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Ianalumab Monoclonal antibody

Indications